Pustular Psoriasis
Spevigo prevents generalized pustular psoriasis flares up to 48 weeks
Spevigo met its primary and key secondary endpoints in a phase 2b trial evaluating the drug for the treatment of adolescents and adults with generalized pustular psoriasis, Boehringer Ingelheim announced in a press release.
Generalized pustular psoriasis lacks advanced treatment options
An unmet need exists to treat generalized pustular psoriasis and its flares, leading many patients to seek emergency or inpatient treatment, according to a study.
FDA approves Spevigo for generalized pustular psoriasis
The FDA has approved Spevigo for the treatment of generalized pustular psoriasis, Boehringer Ingelheim announced in a press release.
Spesolimab efficacious in generalized pustular psoriasis treatment
BOSTON — Patients with generalized pustular psoriasis had a reduction in pustules and increased skin clearance with spesolimab, according to a poster presented at the American Academy of Dermatology Annual Meeting.
Spesolimab may offer hope for patients with generalized pustular psoriasis
The humanized anti-interleukin-36 receptor monoclonal antibody spesolimab demonstrated strong efficacy results with an attractive safety profile in patients with generalized pustular psoriasis, according to a study.
Biologics best other treatments in morbidity, mortality in generalized pustular psoriasis
Things are not always as they seem, but a good H&P should get you back on track
A 17-year-old male comes to your ED with increasing, generalized pruritus and the development of diffuse erythema.